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her husband Mendi (ANC Treasurer-
General and former South African
Ambassador to Britain) separately at
informal occasions.’
'When you get beyond the HIV/AIDS
line, she is a lovely person; I call him
‘Bra Mendi’ and her ‘Aunty,' he
revealed.
Mogari attended the same medical
school with Gwen Ramakgoba
(Gauteng Health MEC) and Molefi
Sefularo (North West Health MEC) and
has 'good relationships' with them.
While SAMA would continue to
highlight legislative issues affecting
doctors, 'we are committed to become
an integral part of the health care
delivery system in partnership with the
government'.
He said SAMA's actions should 'not
be viewed in a negative light, but as a
way of highlighting the issues to a
public that is not fully informed'.
Mogari, who completed a Wits
Business School certificate programme
in finance and accounting cum laude
emphasised that the current problems
extended 'well beyond government' into 
the private sector and health care
funding.
Yet one of his first tests will be
enrolling government into using GPs
(who see over 50% of South Africa's
patients) as a vital platform for
dispensing antiretroviral drugs —
reliably learnt to be a key
recommendation of the cabinet AIDS
task team.
Whether the new 'good cop, bad cop'
team can pull that one off in the face of
'sloppy' new dispensing legislation
disadvantaging both patients and
doctors, remains to be seen.
Chris Bateman
South Africa's new drug pricing
committee, committed to 'dramatically'
slashing overall drug prices and putting
quality medicines within reach of many
more people, is under considerable time
pressure to complete the most difficult
and contentious chunk of its work.
Section 18A of the Medicines Control
Amendment Act, which prevents
anyone from supplying medicine via a
bonus system, rebate system or any
other incentive scheme, is due for
implementation on 2 May 2004.
According to the committee
chairperson, health economist Diane
McIntyre, some stakeholders feel that it
would be best if regulations arising
from the pricing committee's
recommendations came into effect at the
same time as Section 18A.
McIntyre emphasised that it was
'crucial' for all those involved in the
manufacture, distribution and
dispensing of medicines to recognise
that Section 18A is not part of the
pricing committee's terms of reference
and that it will come into effect on 2
May 2004 in terms of the 'Presidential
proclamation on this Act'. 
'We're under pressure to come up
with proposals and to have something
in place by the time this section kicks in.
Everyone agrees that the time frame is
short. But the bottom line is we'll pull
out all the stops to try to meet the
deadline.'
She did, however, say that she would
refuse to compromise if her committee
felt they were not in a position to put
forward sound and solid
recommendations.
‘If we can't defend and argue strongly
for our recommendations, we'll not
consider ourselves bound by this time
frame — at the end of the day we want
our recommendations to be based on
good information.’
The pricing committee's functions
include:
•The introduction of a transparent 
pricing system, including a single 
exit price for all medicines and 
scheduled substances. 
•Determination of an appropriate 
dispensing fee to be charged by 
pharmacists or any person licensed 
to dispense in terms of the Act. 
•Determination of an appropriate fee 
to be charged by the wholesalers or 
distributors or any person selling 
medicines that do not require 
prescription.  
At the time of the SAMJ interview (17
September) McIntyre indicated that she
was busy trying to establish from the
Ministry of Health when the
representatives from the Treasury and
Trade and Industry would be appointed
to her committee.
She said these members needed to be
on board before the committee could
come up with its recommendations. 
‘I'm confident that it will happen
quite quickly because everyone regards
this work as really important and
urgent. In the meantime we can collect
information and start doing some
thinking.’ She said all committee
members were appointed on the basis of
technical expertise. 
She appealled to doctors 'to
understand that it's going to be difficult
to have detailed consultations with
people before we put together our draft
recommendations'.  As evidence of the
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If a feature of Letlape's
chairmanship has been to play
'bad cop' to the government’s
recalcitrance around health
issues, Mogari seems well set
to play the 'good cop'.
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bona fides of her committee, McIntyre
pointed to information-gathering
'legwork' done by a pricing committee
working group that took detailed inputs
from a range of stakeholders at the end
of last year. 
'We have a clear picture of who the
key players are, how it works and what
people's thinking is around this
initiative.'
She made an appeal for all further
inputs to be 'brief and in writing',
saying the sooner they reached her, the
more likely it was that they would
impact on the draft recommendations.
On dispensing fees, the subject of
much rumour and conjecture among
doctors, McIntyre said the legislation
made no mention of a 'flat rate'.
'Some argue that it should be a
percentage value of the drugs and
others say a flat professional fee — this
is all stuff we will probe. What has to be
realised is that the ultimate purpose and
guiding light of the pricing committee is
that the price of medicines in the private
sector is too high and one needs to bring
it down.'
She saw her task as 'interrogating
every aspect' contributing to the high
price of medicines.
'At the end of the day there will be
downward pressure all along the chain.'
One of the greatest difficulties facing
the committee was the lack of
information and transparency — key
elements of its terms of reference.
'It's become just about impossible to
work out what's legitimate and what's
gravy-train,' she observed.
McIntyre said pharmaceutical
members of her committee would
'disagree strongly' with suggestions that
the seasoned drug industry would
succeed in pulling the wool over their
eyes.
'We have plenty of people who know
exactly how it works and they have
high skills levels.'
She refused to speculate on how
much cheaper the person on the street
would find medicines once
recommendations were adopted, but
said South Africa was out of kilter with
international pricing, with some local
products selling for 120% above the
manufacturer price.
The differences between branded and
generic prices were also far greater
overseas, she said, citing Brazil where
the price gap was a 70% difference
versus a ‘10 - 20% difference here'.
'The extent to which the price of
drugs to consumers declines is also
linked to generic substitution.  You
could say prices will come down by
half, but that will depend on how well
we can interrogate the manufacturer
price and pressure that down to be more
in line with international figures. It's
also about how well we can come up
with distribution and dispensing fees
that adequately compensate for a
professional service but on the other
hand are not excessive.'
Public acceptance of generic
substitution was another big factor in
the ultimate pricing.
McIntyre believes her committee's
ultimate purpose is 'very much in line
with what doctors want for their
patients'.
'Patients need to access treatment
when they need it without jeopardising
their livelihoods — often people have to
borrow money to be able to buy
medicines or even buy less medicine
than they actually need,' she stressed.
'I can't tell you how many people
have said things like they had to stop
taking medicine for chronic depression 
because their medical scheme benefit
ran out.'
The youngest, eldest and poorest
were hardest hit, particularly those in
rural areas who did not have public
health sector access.
‘They can't afford to queue at a clinic
or hospital for hours, so they turn to
private care — financially it's really
difficult.’
McIntyre said she personally found
the de facto situation 'unacceptable —
these kind of things really worry me,
especially when it comes to chronic
medicines'.
She said her committee would
obviously include AIDS-related drugs in
their focus, but would take its lead from
the antiretroviral (ARV) roll-out task
team and assist on specifics if requested.
‘There's so much time pressure to get
the overall pricing system in place.’
A related development is the release
of preliminary results of research into
the cost of adult ARV treatment done by
the Health Economics Unit and the
Public Health Department (both at
UCT), and Medecins Sans Frontieres,
which show it to be highly effective
when compared with the costs of
treating AIDS-related opportunistic
diseases.
The incremental cost of ART was
shown to be R8 765 per life year gained
and its incremental effectiveness was
6.04 life years gained.
Chris Bateman
‘If we can't defend and
argue strongly for our
recommendations, we'll not
consider ourselves bound by
this time frame — at the end
of the day we want our
recommendations to be based
on good information.’
